File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: NVR 3-778, a first-in-class HBVCORE inhibitor, alone and incombination with Peg-interferon (PEGIFN), in treatment naive HBeAg-Positive patients: early reductions in HBV DNA and HBeAg

TitleNVR 3-778, a first-in-class HBVCORE inhibitor, alone and incombination with Peg-interferon (PEGIFN), in treatment naive HBeAg-Positive patients: early reductions in HBV DNA and HBeAg
Authors
Issue Date2016
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The International Liver Congress™ 2016 - The 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016), Barcelona, Spain, 13-17 April, 2016. In Journal of Hepatology, 2016, v. 64 n. 2 suppl., p. S210-S211, abstract no. LB06 How to Cite?
AbstractINTRODUCTION: Enhanced rates of durable efficacy in chronic hepatitis B (CHB) patients will likely require combinations of potent agents with complementary mechanisms of action. NVR 3-778 is a first-inclass HBV core inhibitor which may inhibit multiple core-mediated functions in the HBV life cycle. We report data for NVR 3-778, alone and in combination with PegIFN, from a Phase 1b trial in CHB patients …
DescriptionLate Breakers Oral Presentations: no. LB06
Persistent Identifierhttp://hdl.handle.net/10722/234179
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570

 

DC FieldValueLanguage
dc.contributor.authorYuen, RMF-
dc.contributor.authorKim, DJ-
dc.contributor.authorWeilert, F-
dc.contributor.authorChan, HLY-
dc.contributor.authorLalezari, JP-
dc.contributor.authorHwang, SG-
dc.contributor.authorNguyen, T-
dc.contributor.authorLiaw, S-
dc.contributor.authorBrown, N-
dc.contributor.authorKlumpp, K-
dc.contributor.authorFlores, O-
dc.contributor.authorHartman, G-
dc.contributor.authorGane, E-
dc.date.accessioned2016-10-14T06:59:38Z-
dc.date.available2016-10-14T06:59:38Z-
dc.date.issued2016-
dc.identifier.citationThe International Liver Congress™ 2016 - The 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016), Barcelona, Spain, 13-17 April, 2016. In Journal of Hepatology, 2016, v. 64 n. 2 suppl., p. S210-S211, abstract no. LB06-
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/234179-
dc.descriptionLate Breakers Oral Presentations: no. LB06-
dc.description.abstractINTRODUCTION: Enhanced rates of durable efficacy in chronic hepatitis B (CHB) patients will likely require combinations of potent agents with complementary mechanisms of action. NVR 3-778 is a first-inclass HBV core inhibitor which may inhibit multiple core-mediated functions in the HBV life cycle. We report data for NVR 3-778, alone and in combination with PegIFN, from a Phase 1b trial in CHB patients …-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatology-
dc.rights© 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.titleNVR 3-778, a first-in-class HBVCORE inhibitor, alone and incombination with Peg-interferon (PEGIFN), in treatment naive HBeAg-Positive patients: early reductions in HBV DNA and HBeAg-
dc.typeConference_Paper-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authorityYuen, RMF=rp00479-
dc.identifier.doi10.1016/S0168-8278(16)00175-6-
dc.identifier.hkuros267683-
dc.identifier.volume64-
dc.identifier.issue2 suppl.-
dc.identifier.spageS210, abstract no. LB06-
dc.identifier.epageS211-
dc.publisher.placeThe Netherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats